AIM: To evaluate the efficacy and the safety of @entity4481 ( @entity11974 )- @entity1286 combination for the treatment of @entity9 ( @entity9 ). METHODS: In this double-blind, randomized, placebo (PL)-controlled crossover study, 40 @entity5 @entity1 with severe @entity9 were randomized into two groups (20 per group): PGB-PL and PL- @entity11974 . @entity1 in the @entity11974 -PL group received @entity11974 plus oral @entity1286 in phase I, and PL plus oral @entity1286 in phase II. The treatment sequence for the PL- @entity11974 group was PL plus oral @entity1286 in phase I, and @entity11974 plus oral @entity1286 in phase II. These 2-week treatment periods were separated by a 1-week washout period. The primary outcome measure was the decrements in @entity1286 dose; secondary outcomes included quantitative assessments of sleep (rated according to the Medical Outcomes Study Sleep Scale), the Constipation Assessment Scale and adverse effects. RESULTS: The mean minimal effective dose of @entity1286 was 184.4        69.9   mg/day in the period of @entity11974 treatments, which was significantly lower than that of PL-controls (228.7        66.9   mg/day; P   <   0.001) and baseline (247.5        80.0   mg/day; P   <   0.001). Compared with PL, @entity11974 resulted in a significant sleep improvement as measured by @entity25 , sleep quantity, and sleep problems index (P   <   0.001), as well as a Constipation Assessment Scale reduction (P   <   0.001). @entity11974 resulted in a higher frequency of @entity2133 and somnolence than PL (P   <   0.05). CONCLUSION: @entity11974 enhances the efficacy of oral @entity1286 and reduces dose-related adverse reactions. The @entity11974 - @entity1286 combination is an effective approach to controlling @entity9 .

Efficacy and safety of XXXX in @entity1 with @entity9 undergoing @entity1286 therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity11974 :: ('MESH:D011456', 'Chemical') :: ['PGB'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2133 :: ('MESH:D014987', 'Disease') :: ['dry mouth'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity4481 :: ('MESH:C080245', 'Chemical') :: ['pregabalin'] @entity9 :: ('MESH:D009437', 'Disease') :: ['NCP', 'neuropathic cancer pain']
@entity4481 :: (MESH:C080245,Chemical) :: ['pregabalin']
